Since the PI3K/Akt pathway is frequently upregulated in many cancers and a major actor in tumorigenesis, a number of PI3K and Akt inhibitors are currently being evaluated in clinical trials or already approved for clinical use in cancer [36]. Here, AKT1 is linked to cancer.